Brief: Astellas Pharma Inc: China's National Medical Products Administration Approves PADCEV For Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
20/08/2024 24:32
Aug 20 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC - CHINA'S NATIONAL MEDICAL PRODUCTS
ADMINISTRATION APPROVES PADCEV FOR TREATMENT OF LOCALLY ADVANCED
OR METASTATIC UROTHELIAL CANCER
* ASTELLAS PHARMA INC - HAS ALREADY REFLECTED THE IMPACT
FROM THE
APPROVAL FOR ENFORTUMAB VEDOTIN IN CHINA IN ITS FINANCIAL
FORECAST FOR THE CURRENT FISCAL YEAR ENDING MARCH 31, 2025
Source text for Eikon: ID:nTSts8b2c2
Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn